Please use this identifier to cite or link to this item:
https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3844
Journal Title: | Cost-Effectiveness of Tenecteplase Before Thrombectomy for Ischemic Stroke |
Authors: | Gao, Lan Moodie, Marj Mitchell, Peter J. Churilov, Leonid Kleinig, Timothy J. Yassi, Nawaf Yan, Bernard Parsons, Mark W. Donnan, Geoffrey A. Davis, Stephen M. Campbell, Bruce C. V. EXTEND-IA TNK Investigators |
Keywords: | Combined Modality Therapy Cost-Benefit Analysis Emergency Service Endovascular Procedures Fibrinolytic Agents Hospitalization Humans Ischemic Stroke Markov Chains Mortality Patient Readmission Quality-Adjusted Life Years Randomized Controlled Trials as Topic Recurrence Stroke Rehabilitation Tenecteplase Thrombectomy Tissue Plasminogen Activator United States Infarction Stroke Tenecteplase Thrombectomy |
Issue Date: | 2020 |
Date Accessioned: | 2023-04-24T02:44:19Z |
Date Available: | 2023-04-24T02:44:19Z |
Accession Number: | 33023423 |
Url: | https://www.ncbi.nlm.nih.gov/pubmed/33023423 |
Description Affiliation: | Deakin Health Economics, Institute of Health Transformation, School of Health and Social Development, Faculty of Health, Deakin University, Melbourne, Australia (L.G., M.M.). Department of Radiology, Royal Melbourne Hospital (P.J.M.), University of Melbourne, Parkville, Australia. Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (L.C., N.Y., B.Y., M.W.P., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Parkville, Australia. Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Australia (L.C.). Department of Neurology, Royal Adelaide Hospital, South Australia, Australia (T.J.K.). Florey Institute of Neuroscience and Mental Health (N.Y., B.C.V.C.), University of Melbourne, Parkville, Australia. Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia (N.Y.). |
Format Startpage: | 3681-3689 |
Source Volume: | 51 |
Issue Number: | 12 |
Notes: | eng 2020/10/08 Stroke. 2020 Dec;51(12):3681-3689. doi: 10.1161/STROKEAHA.120.029666. Epub 2020 Oct 7. |
DOI: | 10.1161/STROKEAHA.120.029666 |
Date: | Dec 2020 |
Abstract: | BACKGROUND AND PURPOSE: Tenecteplase improved functional outcomes and reduced the requirement for endovascular thrombectomy in ischemic stroke patients with large vessel occlusion in the EXTEND-IA TNK randomized trial. We assessed the cost-effectiveness of tenecteplase versus alteplase in this trial. METHODS: Post hoc within-trial economic analysis included costs of index emergency department and inpatient stroke hospitalization, rehabilitation/subacute care, and rehospitalization due to stroke within 90 days. Sources for cost included key study site complemented by published literature and government websites. Quality-adjusted life-years were estimated using utility scores derived from the modified Rankin Scale score at 90 days. Long-term modeled cost-effectiveness analysis used a Markov model with 7 health states corresponding to 7 modified Rankin Scale scores. Probabilistic sensitivity analyses were performed. RESULTS: Within the 202 patients in the randomized controlled trial, total cost was nonsignificantly lower in the tenecteplase-treated patients (40 997 Australian dollars [AUD]) compared with alteplase-treated patients (46 188 AUD) for the first 90 days(P=0.125). Tenecteplase was the dominant treatment strategy in the short term, with similar cost (5412 AUD [95% CI, -13 348 to 2523]; P=0.181) and higher benefits (0.099 quality-adjusted life-years [95% CI, 0.001-0.1967]; P=0.048), with a 97.4% probability of being cost-effective. In the long-term, tenecteplase was associated with less additional lifetime cost (96 357 versus 106 304 AUD) and greater benefits (quality-adjusted life-years, 7.77 versus 6.48), and had a 100% probability of being cost-effective. Both deterministic sensitivity analysis and probabilistic sensitivity analyses yielded similar results. CONCLUSIONS: Both within-trial and long-term economic analyses showed that tenecteplase was highly likely to be cost-effective for patients with acute stroke before thrombectomy. Recommending the use of tenecteplase over alteplase could lead to a cost saving to the healthcare system both in the short and long term. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02388061. |
URI: | https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3844 |
Journal Title: | Stroke |
Type: | Journal Article |
Appears in Collections: | SWH Data Contributions |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.